55 related articles for article (PubMed ID: 8763829)
1. DNA topoisomerase II mutations and resistance to anti-tumor drugs.
Vassetzky YS; Alghisi GC; Gasser SM
Bioessays; 1995 Sep; 17(9):767-74. PubMed ID: 8763829
[TBL] [Abstract][Full Text] [Related]
2. Molecular determinants of etoposide resistance in HL60 cells.
Alghamdi RH; Ahmed F; Ibrahim SM; Pushparaj PN; Schulten HJ; Abuzenadah AM; Almalki AL
Bioinformation; 2022; 18(10):894-899. PubMed ID: 37654838
[TBL] [Abstract][Full Text] [Related]
3. Cancer chemoresistance and its mechanisms: Associated molecular factors and its regulatory role.
Kannampuzha S; Gopalakrishnan AV
Med Oncol; 2023 Aug; 40(9):264. PubMed ID: 37550533
[TBL] [Abstract][Full Text] [Related]
4. The interplay between DNA topoisomerase 2α post-translational modifications and drug resistance.
Lotz C; Lamour V
Cancer Drug Resist; 2020; 3(2):149-160. PubMed ID: 35582608
[TBL] [Abstract][Full Text] [Related]
5. Evolutionary History of TOPIIA Topoisomerases in Animals.
Moreira F; Arenas M; Videira A; Pereira F
J Mol Evol; 2022 Apr; 90(2):149-165. PubMed ID: 35165762
[TBL] [Abstract][Full Text] [Related]
6. hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase II
Kania EE; Carvajal-Moreno J; Hernandez VA; English A; Papa JL; Shkolnikov N; Ozer HG; Yilmaz AS; Yalowich JC; Elton TS
Mol Pharmacol; 2020 Mar; 97(3):159-170. PubMed ID: 31836624
[TBL] [Abstract][Full Text] [Related]
7. Proteomics of Long-Lived Mammals.
Tombline G; Gigas J; Macoretta N; Zacher M; Emmrich S; Zhao Y; Seluanov A; Gorbunova V
Proteomics; 2020 Mar; 20(5-6):e1800416. PubMed ID: 31737995
[TBL] [Abstract][Full Text] [Related]
8. Oncofetal HMGA2 attenuates genotoxic damage induced by topoisomerase II target compounds through the regulation of local DNA topology.
Ahmed SM; Dröge P
Mol Oncol; 2019 Oct; 13(10):2062-2078. PubMed ID: 31271486
[TBL] [Abstract][Full Text] [Related]
9. The Novel C-terminal Truncated 90-kDa Isoform of Topoisomerase II
Kanagasabai R; Karmahapatra S; Kientz CA; Yu Y; Hernandez VA; Kania EE; Yalowich JC; Elton TS
Mol Pharmacol; 2018 May; 93(5):515-525. PubMed ID: 29514855
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Proteomic Profiling of Tachyplesin I Targets in U251 Gliomaspheres.
Li X; Dai J; Tang Y; Li L; Jin G
Mar Drugs; 2017 Jan; 15(1):. PubMed ID: 28106765
[TBL] [Abstract][Full Text] [Related]
11. Effects of an unusual poison identify a lifespan role for Topoisomerase 2 in
Tombline G; Millen JI; Polevoda B; Rapaport M; Baxter B; Van Meter M; Gilbertson M; Madrey J; Piazza GA; Rasmussen L; Wennerberg K; White EL; Nitiss JL; Goldfarb DS
Aging (Albany NY); 2017 Jan; 9(1):68-97. PubMed ID: 28077781
[TBL] [Abstract][Full Text] [Related]
12. Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity.
Bender RP; Jablonksy MJ; Shadid M; Romaine I; Dunlap N; Anklin C; Graves DE; Osheroff N
Biochemistry; 2008 Apr; 47(15):4501-9. PubMed ID: 18355043
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase II, genotoxicity, and cancer.
McClendon AK; Osheroff N
Mutat Res; 2007 Oct; 623(1-2):83-97. PubMed ID: 17681352
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme.
Wilstermann AM; Bender RP; Godfrey M; Choi S; Anklin C; Berkowitz DB; Osheroff N; Graves DE
Biochemistry; 2007 Jul; 46(28):8217-25. PubMed ID: 17580961
[TBL] [Abstract][Full Text] [Related]
15. The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs.
McClendon AK; Osheroff N
Biochemistry; 2006 Mar; 45(9):3040-50. PubMed ID: 16503659
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the DNA-binding domain and identification of the active site residue in the 'Gyr A' half of Leishmania donovani topoisomerase II.
Sengupta T; Mukherjee M; Das R; Das A; Majumder HK
Nucleic Acids Res; 2005; 33(8):2364-73. PubMed ID: 15860773
[TBL] [Abstract][Full Text] [Related]
17. Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalpha.
Vilain N; Tsai-Pflugfelder M; Benoit A; Gasser SM; Leroy D
Nucleic Acids Res; 2003 Oct; 31(19):5714-22. PubMed ID: 14500835
[TBL] [Abstract][Full Text] [Related]
18. Functional dissection of the C-terminal domain of type II DNA topoisomerase from the kinetoplastid hemoflagellate Leishmania donovani.
Sengupta T; Mukherjee M; Mandal C; Das A; Majumder HK
Nucleic Acids Res; 2003 Sep; 31(18):5305-16. PubMed ID: 12954766
[TBL] [Abstract][Full Text] [Related]
19. Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.
Stacey DW; Hitomi M; Chen G
Mol Cell Biol; 2000 Dec; 20(24):9127-37. PubMed ID: 11094065
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of human topoisomerase II by anti-neoplastic benzazolo[3,2-alpha]quinolinium chlorides.
Vivas-Mejía PE; Cox O; González FA
Mol Cell Biochem; 1998 Jan; 178(1-2):203-12. PubMed ID: 9546601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
